These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34093991)

  • 1. Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation.
    Han D; Wang H; Wujieti B; Zhang B; Cui W; Chen BZ
    Comput Struct Biotechnol J; 2021; 19():2761-2774. PubMed ID: 34093991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
    Xue W; Jiao P; Liu H; Yao X
    Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
    Jiao P; Xue W; Shen Y; Jin N; Liu H
    Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
    Fenaux M; Eng S; Leavitt SA; Lee YJ; Mabery EM; Tian Y; Byun D; Canales E; Clarke MO; Doerffler E; Lazerwith SE; Lew W; Liu Q; Mertzman M; Morganelli P; Xu L; Ye H; Zhang J; Matles M; Murray BP; Mwangi J; Zhang J; Hashash A; Krawczyk SH; Bidgood AM; Appleby TC; Watkins WJ
    Antimicrob Agents Chemother; 2013 Feb; 57(2):804-10. PubMed ID: 23183437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir.
    Wang H; Guo C; Chen BZ; Ji M
    Antiviral Res; 2015 Jan; 113():79-92. PubMed ID: 25449363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.
    May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
    Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
    Manjula S; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct Characteristic Binding Modes of Benzofuran Core Inhibitors to Diverse Genotypes of Hepatitis C Virus NS5B Polymerase: A Molecular Simulation Study.
    Han D; Zhao F; Chen Y; Xue Y; Bao K; Chang Y; Lu J; Wang M; Liu T; Gao Q; Cui W; Xu Y
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.
    Aissa Larousse J; Trimoulet P; Recordon-Pinson P; Papuchon J; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
    J Med Virol; 2014 Aug; 86(8):1350-9. PubMed ID: 24760718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Dvory-Sobol H; Voitenleitner C; Mabery E; Skurnac T; Lawitz EJ; McHutchison J; Svarovskaia ES; Delaney W; Miller MD; Mo H
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6599-606. PubMed ID: 25155588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055.
    Wang H; Cui W; Guo C; Chen BZ; Ji M
    Biochem Cell Biol; 2016 Apr; 94(2):147-58. PubMed ID: 26836778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
    Yu H; Fang Y; Lu X; Liu Y; Zhang H
    Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
    Di Maio VC; Cento V; Mirabelli C; Artese A; Costa G; Alcaro S; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2014 May; 58(5):2781-97. PubMed ID: 24590484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients.
    Plaza Z; Soriano V; Gonzalez Mdel M; Di Lello FA; Macias J; Labarga P; Pineda JA; Poveda E
    J Antimicrob Chemother; 2011 Dec; 66(12):2838-42. PubMed ID: 21954459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
    Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
    J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
    Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
    Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
    J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
    Le Pogam S; Kang H; Harris SF; Leveque V; Giannetti AM; Ali S; Jiang WR; Rajyaguru S; Tavares G; Oshiro C; Hendricks T; Klumpp K; Symons J; Browner MF; Cammack N; Nájera I
    J Virol; 2006 Jun; 80(12):6146-54. PubMed ID: 16731953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
    Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
    J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.